DGAT and triglyceride synthesis: a new target for obesity treatment?

Trends Cardiovasc Med. 2000 Jul;10(5):188-92. doi: 10.1016/s1050-1738(00)00066-9.

Abstract

Because triglycerides are considered essential for survival and their synthesis has been thought to occur through a single mechanism, inhibiting triglyceride synthesis has been largely unexplored as a possible target for obesity treatment. However, recent studies indicate that mice lacking acyl CoA:diacylglycerol acyltransferase (DGAT), a key enzyme in triglyceride synthesis, are viable and resistant to diet-induced obesity. Unexpectedly, this resistance is caused by a mechanism involving increased energy expenditure. These findings suggest that inhibiting specific components of triglyceride synthesis, such as DGAT, is feasible and may represent a novel approach to treating obesity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Acyltransferases / metabolism*
  • Animals
  • Diacylglycerol O-Acyltransferase
  • Energy Metabolism
  • Glucose / metabolism
  • Mice
  • Obesity / metabolism
  • Obesity / therapy*
  • Triglycerides / biosynthesis*
  • Triglycerides / metabolism*

Substances

  • Triglycerides
  • Acyltransferases
  • Dgat1 protein, mouse
  • Diacylglycerol O-Acyltransferase
  • Glucose